Can rivastigimine reduce concomitant psychotropic drug use in AD patients?

The article cites a study related to rivastigimine, conducted by researcher Keith Edwards of Alzheimer's Diagnostic Center, Bennington, Vermont and colleagues, and published in the 2005 issue of the journal "Clinical Drug Investigation." The study showed that 40% of the patients who completed the study who were taking psychotropic drugs at baseline, reduced or discontinued their dose of psychotropic drugs at week 52. Further, they point out that among the patients needing psychotropic drugs at baseline, 85% discontinued, reduced or maintained their dose of psychotropic medication during the 52-week study.